

Gary D Steinberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9321188/publications.pdf>

Version: 2024-02-01

54
papers

2,040
citations

331538

21
h-index

254106

43
g-index

59
all docs

59
docs citations

59
times ranked

2568
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer. <i>Cancer Immunology Research</i> , 2016, 4, 563-568.	1.6	293
2	EFFICACY AND SAFETY OF VALRUBICIN FOR THE TREATMENT OF BACILLUS CALMETTE-GUERIN REFRACTORY CARCINOMA IN SITU OF THE BLADDER. <i>Journal of Urology</i> , 2000, 163, 761-767.	0.2	287
3	Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. <i>Lancet Oncology</i> , The, 2021, 22, 107-117.	5.1	172
4	An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 440-447.	0.8	140
5	Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter Study. <i>Journal of Urology</i> , 2018, 199, 1158-1165.	0.2	82
6	100 years of Bacillus Calmette-Guérin immunotherapy: from cattle to COVID-19. <i>Nature Reviews Urology</i> , 2021, 18, 611-622.	1.9	80
7	Reporting Radical Cystectomy Outcomes Following Implementation of Enhanced Recovery After Surgery Protocols: A Systematic Review and Individual Patient Data Meta-analysis. <i>European Urology</i> , 2020, 78, 719-730.	0.9	73
8	Complete response of renal cell carcinoma vena cava tumor thrombus to neoadjuvant immunotherapy. , 2019, 7, 66.		63
9	Update on the guideline of guidelines: non-muscle-invasive bladder cancer. <i>BJU International</i> , 2020, 125, 197-205.	1.3	63
10	ENERGIZE: a Phase III study of neoadjuvant chemotherapy alone or with nivolumab with/without linrodostat mesylate for muscle-invasive bladder cancer. <i>Future Oncology</i> , 2020, 16, 4359-4368.	1.1	61
11	Quality of Bladder Cancer Information on YouTube. <i>European Urology</i> , 2021, 79, 56-59.	0.9	55
12	Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA - update 2018. <i>Nature Reviews Urology</i> , 2019, 16, 377-386.	1.9	51
13	THE CURRENT STATUS OF BLADDER PRESERVATION IN THE TREATMENT OF MUSCLE INVASIVE BLADDER CANCER. <i>Journal of Urology</i> , 2000, 164, 627-632.	0.2	49
14	KEYNOTE-676: Phase III study of BCG and pembrolizumab for persistent/recurrent high-risk NMIBC. <i>Future Oncology</i> , 2020, 16, 507-516.	1.1	47
15	Systematic Review of Comorbidity and Competing-risks Assessments for Bladder Cancer Patients. <i>European Urology Oncology</i> , 2018, 1, 91-100.	2.6	46
16	Utilization and Outcomes of Nephroureterectomy for Upper Tract Urothelial Carcinoma by Surgical Approach. <i>Journal of Endourology</i> , 2017, 31, 661-665.	1.1	45
17	The effect of surgical approach on performance of lymphadenectomy and perioperative morbidity for radical nephroureterectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 121.e15-121.e21.	0.8	39
18	Current Clinical Trials in Non-muscle-Invasive Bladder Cancer: Heightened Need in an Era of Chronic BCG Shortage. <i>Current Urology Reports</i> , 2019, 20, 84.	1.0	36

#	ARTICLE	IF	CITATIONS
19	Transurethral Resection of Bladder Tumour: The Neglected Procedure in the Technology Race in Bladder Cancer. <i>European Urology</i> , 2020, 77, 669-670.	0.9	30
20	Non-muscle-invasive bladder cancer: An overview of potential new treatment options. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 642-663.	0.8	30
21	International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guérin-exposed High-risk Non-muscle-invasive Bladder Cancer. <i>European Urology</i> , 2022, 82, 34-46.	0.9	30
22	Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin. <i>European Urology</i> , 2020, 78, 387-399.	0.9	28
23	National Surgical Quality Improvement Program surgical risk calculator poorly predicts complications in patients undergoing radical cystectomy with urinary diversion. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 77.e1-77.e7.	0.8	22
24	Implications of micropapillary urothelial carcinoma variant on prognosis following radical cystectomy: A multi-institutional investigation. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 48-56.	0.8	21
25	Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303. <i>Future Oncology</i> , 2021, 17, 3137-3150.	1.1	21
26	Lessons from 151 ureteral reimplantations for postcystectomy ureteroenteric strictures: A single-center experience over a decade. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 112.e19-112.e25.	0.8	18
27	Neoantigen-based personalized cancer vaccines: the emergence of precision cancer immunotherapy. <i>Expert Review of Vaccines</i> , 2022, 21, 173-184.	2.0	17
28	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer. , 2021, 9, e002552.		16
29	Medical Management of Patients with Refractory Carcinoma In Situ of the Bladder. <i>Drugs and Aging</i> , 2001, 18, 335-344.	1.3	13
30	Variability in adherence to guidelines based management of nonmuscle invasive bladder cancer among Society of Urologic Oncology (SUO) members. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 796.e1-796.e6.	0.8	13
31	Non-muscle-invasive Bladder Cancer: Overview and Contemporary Treatment Landscape of Neoadjuvant Chemoablative Therapies. <i>Reviews in Urology</i> , 2020, 22, 43-51.	0.9	9
32	Redefining the implications of nasogastric tube placement following radical cystectomy in the alvimopan era. <i>World Journal of Urology</i> , 2017, 35, 625-631.	1.2	8
33	Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial. <i>European Urology</i> , 2022, 81, 223-228.	0.9	8
34	THE GIANT OF THE GIANT SCHWANNOMAS. <i>Journal of Urology</i> , 1999, 162, 791-792.	0.2	7
35	Safety and Efficacy of Hypofractionated Radiotherapy With Capecitabine in Elderly Patients With Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e12-e18.	0.9	7
36	The association of salvage intravesical therapy following BCG with pathologic outcomes and survival after radical cystectomy for patients with high-grade non-muscle invasive bladder cancer: A multi-institution analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 436.e1-436.e8.	0.8	6

#	ARTICLE	IF	CITATIONS
37	Role of blueâ€light cystoscopy in detecting invasive bladder tumours: data from a multiâ€institutional registry. <i>BJU International</i> , 2022, 130, 62-67.	1.3	6
38	Morphological correlation of urinary bladder cancer molecular subtypes in radical cystectomies. <i>Human Pathology</i> , 2020, 106, 54-61.	1.1	5
39	The safety, tolerability, and efficacy of a neoadjuvant gemcitabine intravesical drug delivery system (TAR-200) in muscle-invasive bladder cancer patients: a phase I trial. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 344.e1-344.e9.	0.8	5
40	Multi-step screening of neoantigensâ€™ HLA- and TCR-interfaces improves prediction of survival. <i>Scientific Reports</i> , 2021, 11, 9983.	1.6	4
41	Utility of Blue Light Cystoscopy for Post-bacillus Calmette-GuÃ©rin Bladder Cancer Recurrence Detection: Implications for Clinical Trial Recruitment and Study Comparisons. <i>Journal of Urology</i> , 2022, 207, 534-540.	0.2	4
42	Safety of repeat blue light cystoscopy with hexaminolevulinate (HAL) in the management of bladder cancer: Results from a phase III, comparative, multi-center study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 382.e1-382.e6.	0.8	3
43	Reduced Dose Intravesical Bacillus Calmette-GuÃ©rin: Why It Might Not Matter. <i>Bladder Cancer</i> , 2022, 8, 113-117.	0.2	2
44	New insights and candidate genes and their implications for care of patients with hereditary prostate cancer. <i>Current Urology Reports</i> , 2000, 1, 9-14.	1.0	1
45	Assessing the conundrum of microscopic haematuria. <i>Nature Reviews Urology</i> , 2016, 13, 700-701.	1.9	1
46	Re: Comparative Effectiveness of Fluorescent versus White Light Cystoscopy for Initial Diagnosis or Surveillance of Bladder Cancer on Clinical Outcomes: Systematic Review and Meta-Analysis. <i>Journal of Urology</i> , 2017, 197, 1359-1360.	0.2	1
47	Editorial Comment. <i>Journal of Urology</i> , 2014, 191, 1763-1763.	0.2	0
48	A review of incidence and relevant risk factors in genitourinary malignancies. <i>Cancer</i> , 2015, 121, 1731-1734.	2.0	0
49	Editorial Comment. <i>Journal of Urology</i> , 2021, 205, 1334-1334.	0.2	0
50	Editorial Comment. <i>Journal of Urology</i> , 2021, 205, 1619-1620.	0.2	0
51	Rethinking the Treatment of Recurrent Nonmuscle-Invasive Bladder Cancer. <i>Journal of Urology</i> , 2021, 206, 7-9.	0.2	0
52	Editorial Comment. <i>Journal of Urology</i> , 2021, 206, 1266-1267.	0.2	0
53	Editorial Comment. <i>Journal of Urology</i> , 2020, 204, 987-988.	0.2	0
54	Effect of neoadjuvant chemotherapy (NAC) on patient preferences for adjuvant treatment in muscle-invasive urothelial carcinoma (MIUC): A multi-country discrete choice experiment (DCE).. <i>Journal of Clinical Oncology</i> , 2022, 40, 454-454.	0.8	0